Endocrine Abstracts

Background: Hypoparathyroidism (HP) is caused by a group of heterogenous conditions that result in deficient secretion of parathyroid hormone. Due to this heterogenous nature, information on HP prevalence is highly variable and studies can be difficult to compare. This study aims to estimate the true prevalence of HP within the EU via comparison of available literature and analyses of sub-populations.Methods: MEDLINE and EMBASE were systematically search...

Background: Adults with growth hormone deficiency (GHD) have increased central fat deposits, hypertriglyceridemia, and hyperglycaemia, with an increased risk of developing metabolic syndrome and cardiovascular disease, conditions that can lead to a diminished quality of life. This study analyzed comorbidities among adults with GHD in the US who had Medicaid or commercial health insurance.Methods: In this retrospective cohort study using IBM Marketscan Me...

Background: Hypoparathyroidism, a rare endocrine disorder characterised by low serum calcium due to low or insufficient parathyroid hormone levels, most commonly occurs post-surgery although can also occur due to predisposing genetic conditions or idiopathically. Hypoparathyroidism requires long-term medical management to minimise complications and detrimental impacts on health-related quality of life. Few real-world studies, particularly in the UK, have quantified healthcare ...

Background: Patients with hypoparathyroidism experience significant physical and cognitive symptoms and reduced health-related quality of life (HRQoL). Conventional therapy for hypoparathyroidism does not fully alleviate diminished HRQoL. The Hypoparathyroidism Patient Experience Scales (HPES) were developed to assess disease-specific physical and cognitive symptoms as well as the impact of hypoparathyroidsm on HRQol. TransCon PTH, an investigational long-acting prodrug of par...

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...